We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+17.28%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.14B
AUM Growth
-$43.5M
Cap. Flow
+$1.54M
Cap. Flow %
0.14%
Top 10 Hldgs %
61.62%
Holding
73
New
4
Increased
21
Reduced
29
Closed
16
Avg Time Held Equity + Options
1.6 years
Top 10 Avg Time Held Equity + Options
1.1 years
Top 20 Avg Time Held Equity + Options
0.8 years
Avg Time Held Equity only
1.7 years
Top 10 Avg Time Held Equity only
1.1 years
Top 20 Avg Time Held Equity only
0.8 years

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$37.9M
2
INSP icon
Inspire Medical Systems
INSP
+$25.6M
3
IMGN icon
Immunogen Inc
IMGN
+$14.9M
4
RVTY icon
Revvity
RVTY
+$14.5M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$12.1M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$23.8M
2
DHR icon
Danaher
DHR
+$16.2M
3
NTRA icon
Natera
NTRA
+$12M
4
AMRX icon
Amneal Pharmaceuticals
AMRX
+$11.2M
5
GSK icon
GSK
GSK
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.59%
2 Miscellaneous 10.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
NTRA icon
1
Natera
NTRA
$56.5B
$141M 12.39%
2,251,588
-241,048
-10% -$12M
2022 Q2
6 quarters
GSK icon
2
GSK
GSK
$99.4B
$110M 9.68%
2,972,954
-286,388
-9% -$10.3M
2018 Q1
23 quarters
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.17B
$73.1M 6.42%
3,383,244
+786,999
+30% +$12.1M
2022 Q2
6 quarters
INSP icon
4
Inspire Medical Systems
INSP
$2.03B
$71.4M 6.28%
351,116
+158,098
+82% +$25.6M
2023 Q2
2 quarters
TEVA icon
5
Teva Pharmaceutical Industries Limited
TEVA
$48.2B
$64.3M 5.64%
6,154,354
-797,731
-11% -$7.45M
2020 Q3
13 quarters
QQQ icon
6
PUT
Invesco QQQ Trust
QQQ
$479B
$61.4M 5.4%
150,000
-250,000
-63% -$94.9M
2023 Q1
3 quarters
SPY icon
7
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$810B
$57M 5.01%
120,000
-120,000
-50% -$53.5M
2023 Q1
3 quarters
UTHR icon
8
United Therapeutics
UTHR
$23.1B
$54.1M 4.76%
246,234
-21,669
-8% -$4.99M
2020 Q2
14 quarters
TECH icon
9
Bio-Techne
TECH
$11.4B
$35.9M 3.15%
465,307
+79,418
+21% +$5.23M
2022 Q4
4 quarters
HQY icon
10
HealthEquity
HQY
$7.66B
$32.8M 2.88%
494,919
+156,403
+46% +$10.8M
2023 Q3
1 quarter
ARGX icon
11
argenx
ARGX
$51.3B
$32.7M 2.87%
85,832
+81,267
+1,780% +$37.9M
2021 Q3
9 quarters
HCA icon
12
HCA Healthcare
HCA
$100B
$31.1M 2.73%
114,805
+4,732
+4% +$1.17M
2023 Q1
3 quarters
CLDX icon
13
Celldex Therapeutics
CLDX
$2.21B
$29.9M 2.63%
754,107
+165,964
+28% +$4.88M
2021 Q4
8 quarters
VERA icon
14
Vera Therapeutics
VERA
$2.01B
$29.5M 2.59%
1,914,830
+436,341
+30% +$5.54M
2022 Q3
5 quarters
CYH icon
15
Community Health Systems
CYH
$413M
$22.6M 1.99%
7,231,126
+85,038
+1% +$229K
2020 Q4
12 quarters
IMGN icon
16
DELISTED
Immunogen Inc
IMGN
$22.2M 1.95%
+748,950
New +$14.9M
2023 Q4
0 quarters
RVTY icon
17
Revvity
RVTY
$17.1B
$20M 1.76%
183,059
+150,361
+460% +$14.5M
2021 Q3
9 quarters
IONS icon
18
Ionis Pharmaceuticals
IONS
$7.17B
$16.4M 1.44%
324,654
+72,208
+29% +$3.46M
2021 Q2
10 quarters
PCVX icon
19
Vaxcyte
PCVX
$10B
$14.7M 1.29%
233,839
+43,409
+23% +$2.25M
2022 Q4
4 quarters
SWAV icon
20
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$14.4M 1.27%
75,822
-8,640
-10% -$1.63M
2023 Q1
3 quarters
THC icon
21
Tenet Healthcare
THC
$21.7B
$14.2M 1.24%
+187,265
New +$11.9M
2023 Q4
0 quarters
PTGX icon
22
Protagonist Therapeutics
PTGX
$8.36B
$12.3M 1.08%
538,074
+251,326
+88% +$4.4M
2023 Q2
2 quarters
ILMN icon
23
Illumina
ILMN
$39.5B
$12.1M 1.06%
89,039
-82,413
-48% -$9.51M
2022 Q1
7 quarters
TARO icon
24
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$10.7M 0.94%
255,988
+665
+0.3% +$24.5K
2019 Q4
16 quarters
KRYS icon
25
Krystal Biotech
KRYS
$9.42B
$10M 0.88%
80,798
-27,973
-26% -$3.1M
2023 Q2
2 quarters
1
2 3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q4 2023 Portfolio in Review

As of Q4 2023, Eversept Partners held 73 positions worth $1.14B, down 3.7% from $1.18B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Eversept Partners's Q4 2023 filing shows 4 new, 21 increased, 29 reduced and 16 closed positions. Its largest new stake was Immunogen Inc: 748,950 shares worth $22.2M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $23.8M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 76% a quarter earlier, followed by Miscellaneous.

  • Eversept Partners's largest Q4 2023 buy was Immunogen Inc: 748,950 shares worth $22.2M.
  • Eversept Partners added most to argenx in Q4 2023, an estimated $37.9M increase.
  • Eversept Partners's biggest Q4 2023 reduction was Danaher, cutting an estimated $16.2M.
  • Eversept Partners fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $23.8M.
  • Eversept Partners's ten largest holdings make up 62% of its $1.14B portfolio in Q4 2023.
  • Eversept Partners opened 4 new positions and closed 16 in Q4 2023.
  • Eversept Partners's portfolio value fell 3.7% quarter-over-quarter to $1.14B.

Based on Eversept Partners's 13F filing for Q4 2023, filed 14 Feb 2024.